Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging

Journal of Neurosurgery

Volumn 107, Issue 3, 2007, Pages 600-609

  Whitmore, Robert G ^a   Krejza, Jaroslaw ^a,c   Kapoor, Gurpreet S ^a   Huse, Jason ^a   Woo, John H ^a   Bloom, Stephanie ^a   Lopinto, Joanna ^a   Wolf, Ronald L ^a   Judy, Kevin ^a   Rosenfeld, Myrna R ^a   Biegel, Jaclyn A ^b   Melhem, Elias R ^a   O'Rourke, Donald M ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Cytogenetics; Loss of heterozygosity; Magnetic resonance imaging; Oligodendroglioma; Perfusion imaging

Indexed keywords

ACCURACY; ADULT; AGED; ALLELE; ARTICLE; CALCULATION; CANCER GRADING; CHROMOSOME 19Q; CHROMOSOME 1P; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOGENETICS; FEMALE; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OLIGODENDROGLIOMA; PERFUSION WEIGHTED IMAGING; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; TUMOR VASCULARIZATION; WHITE MATTER; WORLD HEALTH ORGANIZATION;

ADULT; AGED; BLOOD VOLUME; BRAIN NEOPLASMS; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TUMOR BURDEN;

EID: 34548844744     PISSN: 00223085     EISSN: 00223085     Source Type: Journal    
DOI: 10.3171/JNS-07/09/0600     Document Type: Article

References (34)

1. Ambros PF, Ambros IM: Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. Med Pediatr Oncol 37:492-504, 2001
2. Bauman GS, Ino Y, Ueki K, Zlatescu MC, Fisher BJ, Macdonald DR, et al: Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 48:825-830, 2000
3. Bigner SH, Rasheed BK, Wiltshire R, McLendon RE: Morphologic and molecular genetic aspects of oligodendroglial neoplasms. Neuro Oncol 1:52-60, 1999
4. Cairncross JG, Macdonald DR: Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 23:360-364, 1988
5. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, et al: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479, 1998
6. Chin HW, Hazel JJ, Kim TH, Webster JH: Oligodendrogliomas. I. A clinical study of cerebral oligodendrogliomas. Cancer 45:1458-1466, 1980
7. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK: Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79:1381-1393, 1997
8. Hatanpaa KJ, Burger PC, Eshleman JR, Murphy KM, Berg KD: Molecular diagnosis of oligodendroglioma in paraffin sections. Lab Invest 83:419-428, 2003
9. Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, et al: Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 7:839-845, 2001
10. Kairisto V, Poola A: Software for illustrative presentation of basic clinical characteristics of laboratory tests - GraphROC for Windows. Scand J Clin Lab Invest 55 (222 Suppl):43-60, 1995
11. Kleihues P, Sobin LH: World Health Organization classification of tumors. Cancer 88:2887, 2000
12. Law M, Yang S, Wang H, Babb JS, Johnson G, Cha S, et al: Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 24:1989-1998, 2003
13. Lev MH, Ozsunar Y, Henson JW, Rasheed AA, Barest GD, Harsh GR IV, et al: Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected.] AJNR Am J Neuroradiol 25:214-221, 2004
14. Louis DN, von Deimling A, Seizinger BR: A (CA)n dinucleotide repeat assay for evaluating loss of allelic heterozygosity in small and archival human brain tumor specimens. Am J Pathol 141:777-782, 1992
15. Machein MR, Plate KH: VEGF in brain tumors. J Neurooncol 50:109-120, 2000
16. Maia AC, Malheiros SM, da Rocha AJ, Stavale JN, Guimaraes IF, Borges LR, et al: Stereotactic biopsy guidance in adults with supratentorial nonenhancing gliomas: role of perfusion-weighted magnetic resonance imaging. J Neurosurg 101:970-976, 2004
17. Maia AC Jr, Malheiros SM, da Rocha AJ, da Silva CJ, Gabbai AA, Ferraz FA, et al: MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol 26:777-783, 2005
18. Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J, et al: Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 161:313-319, 2002
19. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, et al: Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 63:1602-1607, 2003
20. Pham CD, Roberts TP, van Bruggen N, Melnyk O, Mann J, Ferrara N, et al: Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest 16:225-230, 1998
21. Preul C, Kuhn B, Lang EW, Mehdorn HM, Heller M, Link J: Differentiation of cerebral tumors using multi-section echo planar MR perfusion imaging. Eur J Radiol 48:244-251, 2003
22. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP: Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145:1175-1190, 1994
23. Sasaki H, Zlatescu MC, Betensky RA, Johnk LB, Cutone AN, Cairncross JG, et al: Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma". J Neuropathol Exp Neurol 61:58-63, 2002
24. Smith JS, Alderete B, Minn Y, Borell TJ, Perry A, Mohapatra G, et al: Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 18:4144-4152, 1999
25. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, et al: Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636-645, 2000
26. van den Bent MJ, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M, et al: Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 21:2525-2528, 2003
27. Walker C, du Plessis DG, Fildes D, Haylock B, Husband D, Jenkinson MD, et al: Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component. Clin Cancer Res 10:7182-7191, 2004
28. Wang J, Alsop DC, Li L, Listerud J, Gonzalez-At JB, Schnall MD, et al: Comparison of quantitative perfusion imaging using arterial spin labeling at 1.5 and 4.0 Tesla. Magn Reson Med 48:242-254, 2002
29. Warmuth C, Gunther M, Zimmer C: Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging. Radiology 228:523-532, 2003
30. Weber MA, Gunther M, Lichy MP, Delorme S, Bongers A, Thilmann C, et al: Comparison of arterial spin-labeling techniques and dynamic susceptibility- weighted contrast-enhanced MRI in perfusion imaging of normal brain tissue. Invest Radiol 38:712-718, 2003
31. White ML, Zhang Y, Kirby P, Ryken TC: Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas? AJNR Am J Neuroradiol 26:784-790, 2005
32. Wolf RL, Wang J, Wang S, Melhem ER, O'Rourke DM, Judy KD, et al: Grading of CNS neoplasms using continuous arterial spin labeled perfusion MR imaging at 3 Tesla. J Magn Reson Imaging 22:475-482, 2005
33. Xu M, See SJ, Ng WH, Arul E, Back MF, Yeo TT, et al: Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors. Neurosurgery 56:919-926, 2005
34. Zlatescu MC, TehraniYazdi A, Sasaki H, Megyesi JF, Betensky RA, Louis DN, et al: Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 61:6713-6715, 2001